The Aminoglycosides Market was valued at USD 1.91 Billion in 2024, and is projected to reach USD 2.45 Billion by 2030, rising at a CAGR of 4.34%. This expected growth in demand can be ascribed to the increasing incidences of animal disease outbreaks leading to high utilization of antibiotics. ![Aminoglycosides Market]( "Aminoglycosides Market")
However, reduction in prescription rate of aminoglycoside antibiotics due to side effects associated with usage of these drugs that include severe ototoxicity, nephrotoxicity, and neuromuscular blockade are expected to affect the market growth negatively. Furthermore, regulatory disapproval for the usage of certain aminoglycoside in regions is also anticipated to attribute for subordinate growth in this industry.
This product will be delivered within 1-3 business days.
However, reduction in prescription rate of aminoglycoside antibiotics due to side effects associated with usage of these drugs that include severe ototoxicity, nephrotoxicity, and neuromuscular blockade are expected to affect the market growth negatively. Furthermore, regulatory disapproval for the usage of certain aminoglycoside in regions is also anticipated to attribute for subordinate growth in this industry.
Aminoglycoside Market Report Highlights
- Tobramycin is expected to exhibit significant growth in the market over the forecast period. It is a potent aminoglycoside antibiotic that plays a critical role in the global aminoglycosides industry due to its broad-spectrum efficacy against Gram-negative bacteria, particularly Pseudomonas aeruginosa.
- Based on route of administration, the market is categorized into injectable, feed, intra-mammary, topical, oral, and injectable, led the market with a market share of 26.73% in 2024.
- Skin infections are anticipated to grow at the fastest CAGR over the forecast period. Skin infections represent a significant driver for the market, owing to their high prevalence and the effectiveness of aminoglycosides in treating gram-negative bacterial infections.
- The North America aminoglycosides industry held 37.60% of the global revenue share in 2024. This large share is attributed to bacterial infections, which are dominant in North America, and a well-established healthcare infrastructure affecting millions of people.
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Route of Administration
1.2.3. Application
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
1.2. Segment Definitions
1.2.1. Product
1.2.2. Route of Administration
1.2.3. Application
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product and route of administration outlook
2.2.2. Application outlook
2.2.3. Regional outlook
2.3. Competitive Insights
2.2. Segment Outlook
2.2.1. Product and route of administration outlook
2.2.2. Application outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Aminoglycosides Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of bacterial infections
3.2.1.2. Advancements in drug development
3.2.1.3. Growing awareness and diagnosis
3.2.2. Market restraint analysis
3.2.2.1. High cost of development
3.2.2.2. Regulatory challenges for new drug approvals
3.3. Aminoglycosides Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pricing Analysis
3.3.4. Pipeline Analysis
3.3.4.1. Phase 1
3.3.4.2. Phase 2
3.3.4.3. Phase 2
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of bacterial infections
3.2.1.2. Advancements in drug development
3.2.1.3. Growing awareness and diagnosis
3.2.2. Market restraint analysis
3.2.2.1. High cost of development
3.2.2.2. Regulatory challenges for new drug approvals
3.3. Aminoglycosides Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pricing Analysis
3.3.4. Pipeline Analysis
3.3.4.1. Phase 1
3.3.4.2. Phase 2
3.3.4.3. Phase 2
Chapter 4. Aminoglycosides Market: Treatment Estimates & Trend Analysis
4.1. Global Aminoglycosides Market: Product Dashboard
4.2. Global Aminoglycosides Market: Product Movement Analysis
4.3. Global Aminoglycosides Market by Product, Revenue
4.4. Neomycin
4.4.1. Neomycin market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Tobramycin
4.5.1. Tobramycin market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Gentamicin
4.6.1. Gentamicin market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Amikacin
4.7.1. Amikacin market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Paromomycin
4.8.1. Paromomycin market estimates and forecasts 2018 to 2030 (USD Million)
4.9. Streptomycin
4.9.1. Streptomycin market estimates and forecasts 2018 to 2030 (USD Million)
4.10. Kanamycin
4.10.1. Kanamycin market estimates and forecasts 2018 to 2030 (USD Million)
4.11. Others
4.11.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
4.2. Global Aminoglycosides Market: Product Movement Analysis
4.3. Global Aminoglycosides Market by Product, Revenue
4.4. Neomycin
4.4.1. Neomycin market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Tobramycin
4.5.1. Tobramycin market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Gentamicin
4.6.1. Gentamicin market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Amikacin
4.7.1. Amikacin market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Paromomycin
4.8.1. Paromomycin market estimates and forecasts 2018 to 2030 (USD Million)
4.9. Streptomycin
4.9.1. Streptomycin market estimates and forecasts 2018 to 2030 (USD Million)
4.10. Kanamycin
4.10.1. Kanamycin market estimates and forecasts 2018 to 2030 (USD Million)
4.11. Others
4.11.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Aminoglycosides Market: Route of Administration Estimates & Trend Analysis
5.1. Global Aminoglycosides Market: Route of Administration Dashboard
5.2. Global Aminoglycosides Market: Route of Administration Movement Analysis
5.3. Global Aminoglycosides Market by Route of Administration, Revenue
5.4. Injectable
5.4.1. Injectable monoclonal antibodies market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Feed
5.5.1. Feed market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Intra-mammary
5.6.1. Intra-mammary market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Topical
5.7.1. Topical market estimates and forecasts 2018 to 2030 (USD Million)
5.8. Oral
5.8.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)
5.2. Global Aminoglycosides Market: Route of Administration Movement Analysis
5.3. Global Aminoglycosides Market by Route of Administration, Revenue
5.4. Injectable
5.4.1. Injectable monoclonal antibodies market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Feed
5.5.1. Feed market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Intra-mammary
5.6.1. Intra-mammary market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Topical
5.7.1. Topical market estimates and forecasts 2018 to 2030 (USD Million)
5.8. Oral
5.8.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Aminoglycosides Market: Application Estimates & Trend Analysis
6.1. Global Aminoglycosides Market: Application Dashboard
6.2. Global Aminoglycosides Market: Application Movement Analysis
6.3. Global Aminoglycosides Market by Application, Revenue
6.4. Skin Infection
6.4.1. Skin infection market estimates and forecasts 2018 to 2030 (USD Million)
6.5. UTI & Pelvic Diseases
6.5.1. UTI & pelvic diseases market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Veterinary
6.6.1. Veterinary market estimates and forecasts 2018 to 2030 (USD Million)
6.7. Respiratory diseases
6.7.1. Respiratory diseases market estimates and forecasts 2018 to 2030 (USD Million)
6.8. Others
6.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
6.2. Global Aminoglycosides Market: Application Movement Analysis
6.3. Global Aminoglycosides Market by Application, Revenue
6.4. Skin Infection
6.4.1. Skin infection market estimates and forecasts 2018 to 2030 (USD Million)
6.5. UTI & Pelvic Diseases
6.5.1. UTI & pelvic diseases market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Veterinary
6.6.1. Veterinary market estimates and forecasts 2018 to 2030 (USD Million)
6.7. Respiratory diseases
6.7.1. Respiratory diseases market estimates and forecasts 2018 to 2030 (USD Million)
6.8. Others
6.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Aminoglycosides Market: Regional Estimates & Trend Analysis by Treatment, Therapeutic Class, and Route of Administration
7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Mexico
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework/ reimbursement structure
7.3.3.3. Competitive scenario
7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Argentina
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Mexico
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework/ reimbursement structure
7.3.3.3. Competitive scenario
7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Argentina
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, by Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2024
8.3.4. Pfizer Inc.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Merck & Co. Inc.
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. AbbVie Inc.
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Teva Pharmaceutical Industries Ltd
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Cipla
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Sun Pharmaceutical Industries Ltd.
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Lupin
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Aurobindo Pharma Limited
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. Fresenius Kabi
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
8.3.13. Viatris Inc.
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Product benchmarking
8.3.13.4. Strategic initiatives
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2024
8.3.4. Pfizer Inc.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Merck & Co. Inc.
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. AbbVie Inc.
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Teva Pharmaceutical Industries Ltd
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Cipla
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Sun Pharmaceutical Industries Ltd.
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Lupin
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Aurobindo Pharma Limited
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. Fresenius Kabi
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
8.3.13. Viatris Inc.
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Product benchmarking
8.3.13.4. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 North America Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 3 North America Aminoglycosides Market, by Route of, 2018-2030 (USD Million)
Table 4 North America Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 5 U.S. Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 6 U.S. Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 7 U.S. Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 8 Canada Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 9 Canada Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 10 Canada Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 11 Mexico Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 12 Mexico Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 13 Mexico Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 14 Europe Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 15 Europe Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 16 Europe Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 17 Germany Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 18 Germany Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 19 Germany Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 20 UK Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 21 UK Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 22 UK Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 23 France Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 24 France Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 25 France Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 26 Italy Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 27 Italy Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 28 Italy Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 29 Spain Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 30 Spain Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 31 Spain Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 32 Asia Pacific Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 33 Asia Pacific Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 34 Asia Pacific Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 35 China Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 36 China Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 37 China Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 38 Japan Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 39 Japan Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 40 Japan Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 41 India Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 42 India Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 43 India Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 44 South Korea Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 45 South Korea Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 46 South Korea Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 47 Latin America Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 48 Latin America Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 49 Latin America Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 50 Brazil Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 51 Brazil Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 52 Brazil Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 53 MEA Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 54 MEA Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 55 MEA Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 56 South Africa Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 57 South Africa Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 58 South Africa Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 59 Saudi Arabia Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 60 Saudi Arabia Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 61 Saudi Arabia Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 62 UAE Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 63 UAE Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 64 UAE Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 65 Kuwait Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 66 Kuwait Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 67 Kuwait Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 2 North America Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 3 North America Aminoglycosides Market, by Route of, 2018-2030 (USD Million)
Table 4 North America Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 5 U.S. Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 6 U.S. Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 7 U.S. Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 8 Canada Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 9 Canada Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 10 Canada Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 11 Mexico Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 12 Mexico Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 13 Mexico Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 14 Europe Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 15 Europe Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 16 Europe Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 17 Germany Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 18 Germany Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 19 Germany Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 20 UK Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 21 UK Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 22 UK Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 23 France Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 24 France Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 25 France Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 26 Italy Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 27 Italy Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 28 Italy Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 29 Spain Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 30 Spain Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 31 Spain Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 32 Asia Pacific Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 33 Asia Pacific Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 34 Asia Pacific Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 35 China Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 36 China Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 37 China Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 38 Japan Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 39 Japan Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 40 Japan Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 41 India Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 42 India Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 43 India Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 44 South Korea Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 45 South Korea Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 46 South Korea Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 47 Latin America Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 48 Latin America Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 49 Latin America Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 50 Brazil Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 51 Brazil Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 52 Brazil Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 53 MEA Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 54 MEA Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 55 MEA Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 56 South Africa Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 57 South Africa Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 58 South Africa Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 59 Saudi Arabia Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 60 Saudi Arabia Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 61 Saudi Arabia Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 62 UAE Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 63 UAE Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 64 UAE Aminoglycosides Market, by Application, 2018-2030 (USD Million)
Table 65 Kuwait Aminoglycosides Market, by Product, 2018-2030 (USD Million)
Table 66 Kuwait Aminoglycosides Market, by Route of Administration, 2018-2030 (USD Million)
Table 67 Kuwait Aminoglycosides Market, by Application, 2018-2030 (USD Million)
List of Figures
Figure 1 Aminoglycosides market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Value chain-based sizing & forecasting
Figure 6 QFD modelling for market share assessment
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Product and route of administration segment snapshot
Figure 10 Application segment snapshot
Figure 11 Competitive landscape snapshot
Figure 12 Pharmaceutical market, (USD Billion)
Figure 13 Market dynamics
Figure 14 Porter’s five forces analysis
Figure 15 PESTLE analysis
Figure 16 Aminoglycosides market: Drug outlook and key takeaways
Figure 17 Aminoglycosides market: Drug movement analysis
Figure 18 Ergot alkaloids market estimates and forecast, 2018-2030 (USD Million)
Figure 19 Non-ergot Aminoglycosides market estimates and forecast, 2018-2030 (USD Million)
Figure 20 Aminoglycosides market: Product outlook and key takeaways
Figure 21 Aminoglycosides market: Product movement analysis
Figure 22 Neomycin market estimates and forecast, 2018-2030 (USD Million)
Figure 23 Tobramycin market estimates and forecast, 2018-2030 (USD Million)
Figure 24 Gentamicin market estimates and forecast, 2018-2030 (USD Million)
Figure 25 Amikacin market estimates and forecast, 2018-2030 (USD Million)
Figure 26 Paromomycin market estimates and forecast, 2018-2030 (USD Million)
Figure 27 Streptomycin market estimates and forecast, 2018-2030 (USD Million)
Figure 28 Kanamycin market estimates and forecast, 2018-2030 (USD Million)
Figure 29 Others market estimates and forecast, 2018-2030 (USD Million)
Figure 30 Aminoglycosides market: Route of administration outlook and key takeaways
Figure 31 Aminoglycosides market: Route of administration movement analysis
Figure 32 Injectablesmarket estimates and forecast, 2018-2030 (USD Million)
Figure 33 Feed market estimates and forecast, 2018-2030 (USD Million)
Figure 34 Intra-mammary market estimates and forecast, 2018-2030 (USD Million)
Figure 35 Topical market estimates and forecast, 2018-2030 (USD Million)
Figure 36 Oral market estimates and forecast, 2018-2030 (USD Million)
Figure 37 Aminoglycosides market: Application outlook and key takeaways
Figure 38 Aminoglycosides market: Application channel movement analysis
Figure 39 Skin Infection market estimates and forecast, 2018-2030 (USD Million)
Figure 40 UTI & Pelvic Diseases market estimates and forecast, 2018-2030 (USD Million)
Figure 41 Veterinary market estimates and forecast, 2018-2030 (USD Million)
Figure 42 Respiratory diseases market estimates and forecast, 2018-2030 (USD Million)
Figure 43 Other diseases market estimates and forecast, 2018-2030 (USD Million)
Figure 44 Aminoglycosides market revenue, by region, 2024 & 2030 (USD Million)
Figure 45 Regional marketplace: Key takeaways
Figure 46 Regional marketplace: Key takeaways
Figure 47 North America Aminoglycosides market estimates and forecasts, 2018-2030 ((USD Million))
Figure 48 Key country dynamics
Figure 49 Target disease prevalence
Figure 50 U.S. Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 51 Key country dynamics
Figure 52 Target disease prevalence
Figure 53 Canada Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 54 Mexico Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 55 Key country dynamics
Figure 56 Target disease prevalence
Figure 57 Europe Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 58 Key country dynamics
Figure 59 Target disease prevalence
Figure 60 UK Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 61 Key country dynamics
Figure 62 Target disease prevalence
Figure 63 Germany Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 64 Key country dynamics
Figure 65 Target disease prevalence
Figure 66 France Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 67 Key country dynamics
Figure 68 Target disease prevalence
Figure 69 Spain Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 70 Key country dynamics
Figure 71 Target disease prevalence
Figure 72 Italy Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 73 Key country dynamics
Figure 74 Target disease prevalence
Figure 75 Denmark Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 76 Key country dynamics
Figure 77 Target disease prevalence
Figure 78 Sweden Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 79 Key country dynamics
Figure 80 Target disease prevalence
Figure 81 Norway Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 82 Rest of Europe Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 83 Asia Pacific Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 84 Key country dynamics
Figure 85 Target disease prevalence
Figure 86 Japan Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 87 Key country dynamics
Figure 88 Target disease prevalence
Figure 89 China Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 90 Key country dynamics
Figure 91 Target disease prevalence
Figure 92 India Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 93 Key country dynamics
Figure 94 Target disease prevalence
Figure 95 Australia Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 96 Key country dynamics
Figure 97 Thailand Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 98 Key country dynamics
Figure 99 South Korea Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 100 Rest of Asia Pacific Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 101 Latin America Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 102 Key country dynamics
Figure 103 Target disease prevalence
Figure 104 Brazil Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 105 Key country dynamics
Figure 106 Target disease prevalence
Figure 107 Argentina Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 108 Rest of Latin America Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 109 MEA Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 110 Key country dynamics
Figure 111 Target disease prevalence
Figure 112 South Africa Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 113 Key country dynamics
Figure 114 Target disease prevalence
Figure 115 Saudi Arabia Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 116 Key country dynamics
Figure 117 Target disease prevalence
Figure 118 UAE Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 119 Key country dynamics
Figure 120 Target disease prevalence
Figure 121 Kuwait Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 122 Rest of MEA Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Value chain-based sizing & forecasting
Figure 6 QFD modelling for market share assessment
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Product and route of administration segment snapshot
Figure 10 Application segment snapshot
Figure 11 Competitive landscape snapshot
Figure 12 Pharmaceutical market, (USD Billion)
Figure 13 Market dynamics
Figure 14 Porter’s five forces analysis
Figure 15 PESTLE analysis
Figure 16 Aminoglycosides market: Drug outlook and key takeaways
Figure 17 Aminoglycosides market: Drug movement analysis
Figure 18 Ergot alkaloids market estimates and forecast, 2018-2030 (USD Million)
Figure 19 Non-ergot Aminoglycosides market estimates and forecast, 2018-2030 (USD Million)
Figure 20 Aminoglycosides market: Product outlook and key takeaways
Figure 21 Aminoglycosides market: Product movement analysis
Figure 22 Neomycin market estimates and forecast, 2018-2030 (USD Million)
Figure 23 Tobramycin market estimates and forecast, 2018-2030 (USD Million)
Figure 24 Gentamicin market estimates and forecast, 2018-2030 (USD Million)
Figure 25 Amikacin market estimates and forecast, 2018-2030 (USD Million)
Figure 26 Paromomycin market estimates and forecast, 2018-2030 (USD Million)
Figure 27 Streptomycin market estimates and forecast, 2018-2030 (USD Million)
Figure 28 Kanamycin market estimates and forecast, 2018-2030 (USD Million)
Figure 29 Others market estimates and forecast, 2018-2030 (USD Million)
Figure 30 Aminoglycosides market: Route of administration outlook and key takeaways
Figure 31 Aminoglycosides market: Route of administration movement analysis
Figure 32 Injectablesmarket estimates and forecast, 2018-2030 (USD Million)
Figure 33 Feed market estimates and forecast, 2018-2030 (USD Million)
Figure 34 Intra-mammary market estimates and forecast, 2018-2030 (USD Million)
Figure 35 Topical market estimates and forecast, 2018-2030 (USD Million)
Figure 36 Oral market estimates and forecast, 2018-2030 (USD Million)
Figure 37 Aminoglycosides market: Application outlook and key takeaways
Figure 38 Aminoglycosides market: Application channel movement analysis
Figure 39 Skin Infection market estimates and forecast, 2018-2030 (USD Million)
Figure 40 UTI & Pelvic Diseases market estimates and forecast, 2018-2030 (USD Million)
Figure 41 Veterinary market estimates and forecast, 2018-2030 (USD Million)
Figure 42 Respiratory diseases market estimates and forecast, 2018-2030 (USD Million)
Figure 43 Other diseases market estimates and forecast, 2018-2030 (USD Million)
Figure 44 Aminoglycosides market revenue, by region, 2024 & 2030 (USD Million)
Figure 45 Regional marketplace: Key takeaways
Figure 46 Regional marketplace: Key takeaways
Figure 47 North America Aminoglycosides market estimates and forecasts, 2018-2030 ((USD Million))
Figure 48 Key country dynamics
Figure 49 Target disease prevalence
Figure 50 U.S. Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 51 Key country dynamics
Figure 52 Target disease prevalence
Figure 53 Canada Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 54 Mexico Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 55 Key country dynamics
Figure 56 Target disease prevalence
Figure 57 Europe Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 58 Key country dynamics
Figure 59 Target disease prevalence
Figure 60 UK Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 61 Key country dynamics
Figure 62 Target disease prevalence
Figure 63 Germany Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 64 Key country dynamics
Figure 65 Target disease prevalence
Figure 66 France Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 67 Key country dynamics
Figure 68 Target disease prevalence
Figure 69 Spain Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 70 Key country dynamics
Figure 71 Target disease prevalence
Figure 72 Italy Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 73 Key country dynamics
Figure 74 Target disease prevalence
Figure 75 Denmark Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 76 Key country dynamics
Figure 77 Target disease prevalence
Figure 78 Sweden Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 79 Key country dynamics
Figure 80 Target disease prevalence
Figure 81 Norway Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 82 Rest of Europe Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 83 Asia Pacific Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 84 Key country dynamics
Figure 85 Target disease prevalence
Figure 86 Japan Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 87 Key country dynamics
Figure 88 Target disease prevalence
Figure 89 China Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 90 Key country dynamics
Figure 91 Target disease prevalence
Figure 92 India Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 93 Key country dynamics
Figure 94 Target disease prevalence
Figure 95 Australia Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 96 Key country dynamics
Figure 97 Thailand Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 98 Key country dynamics
Figure 99 South Korea Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 100 Rest of Asia Pacific Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 101 Latin America Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 102 Key country dynamics
Figure 103 Target disease prevalence
Figure 104 Brazil Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 105 Key country dynamics
Figure 106 Target disease prevalence
Figure 107 Argentina Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 108 Rest of Latin America Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 109 MEA Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 110 Key country dynamics
Figure 111 Target disease prevalence
Figure 112 South Africa Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 113 Key country dynamics
Figure 114 Target disease prevalence
Figure 115 Saudi Arabia Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 116 Key country dynamics
Figure 117 Target disease prevalence
Figure 118 UAE Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 119 Key country dynamics
Figure 120 Target disease prevalence
Figure 121 Kuwait Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Figure 122 Rest of MEA Aminoglycosides market estimates and forecasts, 2018-2030 (USD Million)
Companies Mentioned
The companies profiled in this Aminoglycosides market report include:- Pfizer Inc.
- Merck & Co., Inc.
- AbbVie Inc.
- Teva Pharmaceutical Industries
- Cipla Limited
- Sun Pharmaceutical Industries
- Lupin Limited
- Aurobindo Pharma
- Fresenius Kabi
- Viatris Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 105 |
| Published | April 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 1.91 Billion |
| Forecasted Market Value ( USD | $ 2.45 Billion |
| Compound Annual Growth Rate | 4.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
